Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/14856

o-Nitrotoluene: Target Organs and Levels of Evidence for TR-504

Toxicology and Carcinogenesis Studies ofo-Nitrotoluene (CASRN 88-72-2) in F344/N Rats and B6C3F1 Mice (Feed Studies)

Chemical (Study Title)
CASRN		Peer Review DateRoute/Exposure LevelsStudy Laboratory
o-Nitrotoluene
88-72-2		05/03/2001Dosed-Feed
MR: 0, 625, 1250, 2000, OR 5000 PPM FR: 0, 625, 1250, OR 2000 PPM M: 0, 1250, 2500, OR 5000 PPM; 60/SEX/DOSE		Southern Research Institute

Levels of Evidence

Male Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): MALIGNANT MESOTHELIOMA 2/60 20/60 29/60 44/60 44/60 54/60
  • Skin: (SUBCUTANEOUS) LIPOMA 0/60 4/60 13/60 13/60 10/60 12/60 FIBROMA 5/60 46/60 52/60 59/60 45/60 52/60 FIBROSARCOMA 0/60 7/60 17/60 20/60 8/60 12/60 COMBINED 5/60 47/60 55/60 59/60 47/60 53/60
  • Mammary Gland: FIBROADENOMA 0/60 7/60 10/60 2/60 13/60 20/60
  • Liver: ADENOMA 2/60 3/60 3/60 7/60 3/60 4/60 ADENOMA OR CARCINOMA 3/60 3/60 3/60 8/60 3/60 6/60 CHOLANGIOCARCINOMA 0/60 0/60 0/60 0/60 0/60 3/60 HEPATOCHOLANGIOCARCINOMA 0/60 1/60 0/60 1/60 0/60 0/60
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 5/60 1/60 2/60 3/60 8/60 OR ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 2/60 5/60 1/60 2/60 3/60 11/60
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCUS; MIXED CELL FOCUS; CLEAR CELL FOCUS; MIXED CELL CELLULAR INFILTRATION
  • BONE MARROW: HYPERPLASIA
  • SPLEEN: HEMATOPOIETIC CELL PROLIFERATION
  • LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA
Other Considerations
  • DECREASED INCIDENCES: (MONONUCLEAR CELL LEUKEMIA) 30/60 21/60 3/60 3/60 13/60 1/60
  • DECREASED INCIDENCES: (TESTIS: INTERSTITIAL CELL ADENOMA) 55/60 53/60 51/60 46/60 50/60 27/50
Female Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Skin: (SUBCUTANEOUS) FIBROMA 3/60 3/60 18/60 20/60 FIBROMA OR FIBROSARCOMA 3/60 3/60 21/60 22/60
  • Mammary Gland: FIBROADENOMA 23/60 47/60 52/60 56/60
May Have Been Related
  • Liver: ADENOMA 1/60 0/59 1/60 6/60
Non-Neoplastic Lesions
  • MAMMARY GLAND: HYPERPLASIA
  • LIVER: EOSINOPHILIC FOCUS; MIXED CELL FOCUS, CLEAR CELL FOCUS; BASOPHILIC FOCUS
  • BONE MARROW: HYPERPLASIA
  • SPLEEN: HEMATOPOIETIC CELL PROLIFERATION
  • LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA
  • LYMPH NODE (MANDIBULAR): LYMPHOID HYPERPLASIA
Other Considerations
  • DECREASED INCIDENCES: (MONONUCLEAR CELL LEUKEMIA) 21/60 6/60 4/60 5/60
Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Hematopoietic System: HEMANGIOSARCOMA 4/60 17/60 55/60 60/60
  • Intestines: (CECUM) CARCINOMA 0/60 12/60 9/60 0/60
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCUS; BASOPHILIC FOCUS, HEPATOCYTE NECROSIS; FOCAL HEPATOCYTE SYNCYTIAL ALTERATION
  • KIDNEY: TUBULAR PIGMENTATION
  • NASAL CAVITY: OLFACTORY EPITHELIUM DEGENERATION
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Hematopoietic System: HEMANGIOSARCOMA 0/60 2/60 3/60 50/60
  • Intestines: (CECUM) CARCINOMA 0/60 1/60 4/60 3/60
  • Liver: ADENOMA 7/60 5/59 19/59 29/60 CARCINOMA 2/60 4/59 6/59 16/60 COMBINED 9/60 9/59 24/59 39/60
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCUS; BASOPHILIC FOCUS; HEPATOCYTE NECROSIS; FOCAL HEPATOCYTE NECROSIS; FOCAL HEPATOCYTE CYTOPLASMIC VACUOLIZATION
  • KIDNEY: TUBULAR PIGMENTATION
  • NASAL CAVITY: OLFACTORY EPITHELIUM DEGENERATION